Logo
x

Search

Subscribe Now

Pharmaceutical

Jane Reed Highlights the Growing Dependence of NLP to Comply with the Regulatory Guidelines

Jane Reed Highlights the Growing Dependence of NLP to Comply with the Regulatory Guidelines

  • November 17, 2023
Multichannel Marketing Tactics in Pharma: Harnessing the Power of Digital

Multichannel Marketing Tactics in Pharma: Harnessing the Power of Digital

  • June 9, 2023
Rhythm's Imcivree (setmelanotide) Receives the US FDA's Approval for Chronic Weight Management in Patients with Obesity

Rhythm's Imcivree (setmelanotide) Receives the US FDA's Approval for Chronic Weight Management in Patients with Obesity

  • November 27, 2020
ITROM Pharmaceutical Signs an Exclusive License & Commercialization Agreement with Mithra for 20 years

ITROM Pharmaceutical Signs an Exclusive License & Commercialization Agreement with Mithra for 20 years

  • February 13, 2019
Rafael Pharmaceuticals' Devimistat (CPI-613) Receives EMA's ODD for R/R Acute Myeloid Leukemia (AML) and Metastatic Pancreatic Cancer (mPC)

Rafael Pharmaceuticals' Devimistat (CPI-613) Receives EMA's ODD for R/R Acute Myeloid Leukemia (AML) and Metastatic Pancreatic Can...

  • January 11, 2019
Disease of the Month – Lennox-Gastaut syndrome (LGS)

    Disease of the Month – Lennox-Gastaut syndrome (LGS)

    • March 26, 2025
    New Drug Designations - February 2025

      New Drug Designations - February 2025

      • March 25, 2025
      Merck Partners with Jiangsu Hengrui Pharmaceuticals for HRS-5346, Expanding its Cardio-Metabolic Portfolio

        Merck Partners with Jiangsu Hengrui Pharmaceuticals for HRS-5346, Expanding its Cardio-Metabolic Portfolio

        • March 25, 2025
        Alumis and Kaken Pharmaceutical Enter Collaboration & Licencing Deal for ESK-001’s Development & Commercialization in Japan

          Alumis and Kaken Pharmaceutical Enter Collaboration & Licencing Deal for ESK-001’s Development & Commercialization in Japan

          • March 25, 2025
          Paratek Pharmaceuticals to Acquire Optinose for ~$330M, Expanding its Commercial Portfolio

            Paratek Pharmaceuticals to Acquire Optinose for ~$330M, Expanding its Commercial Portfolio

            • March 21, 2025
            Alnylam Pharmaceuticals Reports the US FDA’s Approval of Amvuttra (Vutrisiran) to Treat ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)

              Alnylam Pharmaceuticals Reports the US FDA’s Approval of Amvuttra (Vutrisiran) to Treat ATTR Amyloidosis with Cardiomyopathy (ATTR...

              • March 21, 2025
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.